Resultados de la búsqueda 21-30 of 13948 for Raised platelets

  1. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    ... high (80-90%) frequency of MUC1 expression and variably high ... platelets ≥ 100,000 /microliter, performed within 7 days prior to the collection.

  2. Hematología - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  3. Hematología - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  4. Neurología - Ensayos clínicos - Mayo Clinic

    ... high (80-90%) frequency of MUC1 expression and variably high ... platelets ≥ 100,000 /microliter, performed within 7 days prior to the collection.

  5. Hematología - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  6. Neurología - Ensayos clínicos - Mayo Clinic

    ... high (80-90%) frequency of MUC1 expression and variably high ... platelets ≥ 100,000 /microliter, performed within 7 days prior to the collection.

  7. Hematología - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...

  8. Oncología (médica) - Ensayos clínicos - Mayo Clinic

    Despite not needing therapy, these patients have significant immune dysfunction. This may lead to an increased risk of serious infections requiring ...

  9. Trombocitosis - Síntomas y causas - Mayo Clinic

    Platelet disorders: Thrombocythemia and thrombocytosis. National Heart, Lung, and Blood Institute. https://www.nhlbi.nih.gov/health/thrombocythemia ...

  10. Hematología - Ensayos clínicos - Mayo Clinic

    This phase III trial studies whether inotuzumab ozogamicin added to post-induction chemotherapy for patients with High-Risk B-cell Acute Lymphoblastic Leukemia ...